Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adsorbed acellular diphtheria, tetanus, and acellular pertussis, inactivated poliovirus, and Haemophilus influenzae type b combined vaccine
- Development stage
- Unknown
- Lead developer
- Beijing Minhai Biological
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The adsorbed acellular diphtheria, tetanus, and acellular pertussis, inactivated poliovirus, and Haemophilus influenzae type b combined vaccine (DTaP-IPV-Hib) is a pentavalent combination vaccine under development by Beijing Minhai Biotechnology Co., Ltd., a subsidiary of Shenzhen Kangtai Biological Products. This biologic product is composed of multiple active antigenic components: diphtheria and tetanus toxoids, acellular pertussis antigens, inactivated poliovirus (types 1, 2, and 3), and Haemophilus influenzae type b (Hib) conjugate. It is designed to simultaneously prevent five major infectious diseases in infants and young children: diphtheria, tetanus, pertussis (whooping cough), poliomyelitis, and invasive Hib infections. The vaccine is currently being evaluated in Phase 1 clinical trials in China to assess its safety and immunogenicity.
- Other names
- adsorbed acellular DTaP-IPV-Hib combined vaccineDTaP-IPV-Hib pentavalent vaccine
02
Targets
BCR (Immunoglobulin G B Cell Receptor)
Beyond the preview
Go deeper on adsorbed acellular diphtheria, tetanus, and acellular pertussis, inactivated poliovirus, and Haemophilus influenzae type b combined vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adsorbed acellular diphtheria, tetanus, and acellular pertussis, inactivated poliovirus, and Haemophilus influenzae type b combined vaccine.